The independent source for health policy research, polling, and news.
441-460 of 477 results
Innate Immunotherapeutics, whose largest shareholder is Buffalo-area Rep. Chris Collins, received FDA approval to begin U.S. trials of its drug for treating advanced multiple sclerosis.
More than 70 drugs approved from 2001 through 2010 ran into safety concerns later that resulted in withdrawals from the market, 鈥渂lack box鈥 warnings or other actions.
Even as drug pricing issues continue to draw scrutiny, federal safety regulations and incentives offer drug companies a new avenue to get a sweet return on their development costs.
The medical supply industry makes a particularly revelatory case study of the difficulties of untangling global trade.
With high-level connections in the Capitol, Parker "Pete" Petit aims to resolve regulatory issues that have haunted his wound care company.
Sen. Bernie Sanders鈥 bill to allow Americans to buy cheaper medicines from Canada would bypass a requirement that blocked past legislative efforts over two decades.
Marathon, maker of an expensive treatment for Duchenne muscular dystrophy, sells the drug for $140 million in cash and stock to PTC Therapeutics.
The numbers show that President Trump鈥檚 choice for FDA commissioner, Scott Gottlieb, has long-standing ties to pharmaceutical companies as a board member or consultant and that he had to recuse himself multiple times while working at the FDA.
Amid an uproar over high drug prices, three GOP senators are asking the Government Accountability Office to investigate whether the Orphan Drug Act is being abused.
More than 30 states have laws on the books to allow dying patients the right to try experimental treatments. But these treatments may not be covered by insurance, and ethicists worry vulnerable people could be exploited near the end of their lives. The laws may also duplicate a process the FDA already has in place.
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
After a tough fight by Democrats, Senate Republicans confirmed Rep. Tom Price鈥檚 nomination to head the Department of Health and Human Services. He will have the authority to upend some current practices.
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren鈥檛 new or were repurposed multiple times, an investigation shows.
The scourge of the Middle Ages could still be pretty scary as a bioterrorism weapon, so scientists are trying to find a way to immunize people against it.
Lawyers who deposed top company officials in a civil case say they declined to answer questions about their failure to warn American hospitals of infection risks. Industry giant Olympus also is the subject of a criminal probe.
A breakdown of winners 鈥 and a few losers 鈥 in the sprawling Cures Act approved by the House.
The federal agency took 14 months to warn the public about the potential for infections. Officials say they acted as fast as they could.
Three lobbyists for every member of Congress in a push to pass a bill that increases research funding and speeds up approvals.
The legislation would give federal officials more flexibility in evaluating the effectiveness and safety of drugs and devices and add billions of dollars to NIH funding. But critics say it could endanger patients鈥 safety and doesn鈥檛 do enough to stop spiraling drug prices.
漏 2026 KFF